Literature DB >> 14583679

Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors.

Mary F Hebert1, Amy L Dowling, Cynthia Gierwatowski, Yvonne S Lin, Karen L Edwards, Connie L Davis, Christopher L Marsh, Erin G Schuetz, Kenneth E Thummel.   

Abstract

OBJECTIVE: Renal dysfunction is a common and costly adverse outcome of long-term treatment with calcineurin inhibitors (CNIs). We conducted a retrospective, case-control study to test whether the risk of renal dysfunction in liver transplantation patients receiving CNIs is associated with the 2677G>T transversion in exon-21 of the gene (ABCB1) encoding P-glycoprotein. A total of 120 non-Hispanic white patients were evaluated.
RESULTS: The overall incidence of renal dysfunction by year 3 post-transplantation was 40%. The frequency of renal dysfunction was reduced among patients with an ABCB1 2677TT genotype, as compared to those with a 2677GG genotype. Subjects with a heterozygote genotype behaved phenotypically like the 2677GG group. Comparing those subjects with a 2677TT genotype to the combined group of subjects with a 2677GG, TG, AT, or AG genotype resulted in an odds ratio of 0.26 (0.09-0.77). When subjects were stratified by gender, the frequency of renal dysfunction was reduced among men with an ABCB1 2677TT genotype, relative to men with different genotypes. A similar odds ratio was obtained for women, but it did not achieve significance. When 18 subjects with an elevated SCr concentration just prior to surgery were excluded from the year 3 analysis, the association between the 2677TT genotype and chronic renal dysfunction in the remaining cohort was strengthened comparing genotype groups.
CONCLUSIONS: Based on these results, we conclude that homozygosity for the ABCB1 2677T (S893) allele is associated with reduced risk of chronic renal dysfunction among liver transplantation patients receiving an immunosuppressive regimen containing CNIs. Copyright 2003 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14583679     DOI: 10.1097/00008571-200311000-00002

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  16 in total

Review 1.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

Review 2.  The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis.

Authors:  Caitriona Ryan; Alan Menter; Richard B Warren
Journal:  Mol Diagn Ther       Date:  2010-04-01       Impact factor: 4.074

Review 3.  Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.

Authors:  Christine E Staatz; Lucy K Goodman; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

Review 4.  Kidney Fibrosis: Origins and Interventions.

Authors:  Thomas Vanhove; Roel Goldschmeding; Dirk Kuypers
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

5.  Donor ABCB1 variant associates with increased risk for kidney allograft failure.

Authors:  Jason Moore; Amy Jayne McKnight; Bernd Döhler; Matthew J Simmonds; Aisling E Courtney; Oliver J Brand; David Briggs; Simon Ball; Paul Cockwell; Christopher C Patterson; Alexander P Maxwell; Stephen C L Gough; Gerhard Opelz; Richard Borrows
Journal:  J Am Soc Nephrol       Date:  2012-10-11       Impact factor: 10.121

6.  Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts.

Authors:  Maarten Naesens; Evelyne Lerut; Hylke de Jonge; Boudewijn Van Damme; Yves Vanrenterghem; Dirk R J Kuypers
Journal:  J Am Soc Nephrol       Date:  2009-09-17       Impact factor: 10.121

7.  Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease.

Authors:  Helen E Smith; J P Jones; Thomas F Kalhorn; Federico M Farin; Patricia L Stapleton; Connie L Davis; James D Perkins; David K Blough; Mary F Hebert; Kenneth E Thummel; Rheem A Totah
Journal:  Pharmacogenet Genomics       Date:  2008-11       Impact factor: 2.089

8.  CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition.

Authors:  Songmao Zheng; Yasar Tasnif; Mary F Hebert; Connie L Davis; Yoshihisa Shitara; Justina C Calamia; Yvonne S Lin; Danny D Shen; Kenneth E Thummel
Journal:  Transplantation       Date:  2013-03-27       Impact factor: 4.939

9.  Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium.

Authors:  Pamala A Jacobson; David Schladt; Ajay Israni; William S Oetting; Yi Cheng Lin; Robert Leduc; Weihau Guan; Vishal Lamba; Arthur J Matas
Journal:  Transplantation       Date:  2012-03-27       Impact factor: 4.939

Review 10.  Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.

Authors:  Jeannine S McCune; Meagan J Bemer
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.